<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03569137</url>
  </required_header>
  <id_info>
    <org_study_id>RC17_0463</org_study_id>
    <nct_id>NCT03569137</nct_id>
  </id_info>
  <brief_title>Post-Ibrutinib Colitis and Intestinal Microbiota</brief_title>
  <acronym>COLMI</acronym>
  <official_title>Identification of Intestinal Microbiota Biomarkers Predictive of Diarrhea in Patients Treated by Ibrutinib.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vendee Departmental hospital center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Identify gut microbiome biomarkers associated with colitis in patients treated with targeted
      therapy in hematology
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>difference in microbiome biomarkers between patients developing colitis after exposure to targeted therapy and those not developing colitis</measure>
    <time_frame>At the end of the study, after 2 years.</time_frame>
    <description>With the different species and metabolites between the 2 groups of patients (patients developing diarrhea after exposure to Ibrutinib and those not developing diarrhea), we will create a risk score for occurrence of diarrhea during treatment with Ibrutinib, on the previously developed model (Montassier et al, 2016, Genome medicine)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identify biomarkers of the gut microbiota associated with the occurrence of severe diarrhea (grade 3 and 4 CTCAE, version 4.0) in patients treated with Ibrutinib for malignant hemopathy B.</measure>
    <time_frame>At the end of the study, after 2 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify biomarkers of gut microbiota associated with the occurrence of diarrhea by subgroup: patients treated with Ibrutinib alone, patients treated with Ibrutinib in combination with another molecule</measure>
    <time_frame>At the end of the study, after 2 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creation of a predictive score of the occurrence of diarrhea in patients treated with Ibrutinib for malignant hemopathy B, including the biomarkers of the intestinal microbiome and the clinical characteristics of the patient</measure>
    <time_frame>At the end of the study, after 2 years.</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Gastrointestinal Microbiome</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool samples and blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients hospitalized in the Hematology departments and receiving targeted therapy with
        Ibrutinib
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years

          -  Outside the context of guardianship, -affiliated to the Social Security Regime and

          -  Having consented to participate in the COLMI study.

          -  Patient who benefit of treatment by targeted therapy to Ibrutinib

        Exclusion Criteria:

          -  History of uncontrolled colitis before the start of treatment.

          -  Patient with inflammatory bowel disease.

          -  Patient not consenting to participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emmanuel MONTASSIER, MD</last_name>
    <phone>02 53 48 20 38</phone>
    <phone_ext>+33</phone_ext>
    <email>emmanuel.montassier@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Emmanuel Montassier, MD</last_name>
      <phone>0253482038</phone>
      <email>emmanuel.montassier@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuel Montassier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 14, 2018</study_first_submitted>
  <study_first_submitted_qc>June 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>June 14, 2018</last_update_submitted>
  <last_update_submitted_qc>June 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gut Microbiome</keyword>
  <keyword>hematologic malignancies B</keyword>
  <keyword>biomarkers</keyword>
  <keyword>targeted therapy</keyword>
  <keyword>Gut microbiota</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

